At NG Biotech, we develop, manufacture and commercialise rapid, mobile and connected diagnostics to modernize diagnosis practice worldwide.
NG Biotech is a company specialized in Research & Development, Manufacturing and Marketing of a new generation of “multiplex”, “quantitative” and “connected” rapid diagnostics for biomarker analysis and/or therapy monitoring at the Point of Care. NG Biotech’s patented platform is rapid, mobile and connected. It allows to simultaneously analyse up to 9 biomarkers from a biological direct sample such as a single finger-prick drop of blood. The results can be sent via smartphone within five minutes.
NG Biotech commercializes a range of rapid diagnostic devices covering antimicrobial resistance, women’s health and infectious disease.
NG Biotech Rapid Tests (LFIA) range for detection and identification of the mechanism of antimicrobial resistance (Carbapenemase-R, ESBL-R, Colistin-R, Vancomycin-R) is already a global market leader with sales in over 70 countries, including US and China.
NG Biotech also proposes custom development partnerships with further manufacturing to support breakthrough innovative ideas with rapid diagnostic needs. Backed by a strong R&D team and 30 years of know-how, NG-Biotech is always at the hedge of technology and can conduct projects from feasibility stage up to CE marking and FDA clearance.
